Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

HUNGER

Showing results (1001-1010 of 1,174) with videos related to

Pageof 118
Sort By:
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood|August 9, 2023
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group studyBrent L Wood, Meenakshi Devidas, Ryan J Summers, et al.
Blood|July 1, 2015
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232Michael J Borowitz, Brent L Wood, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Neoplasia (New York, N.Y.)|July 11, 2021
miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patientsAdriana Taveira da Cruz, Aline Hunger, Fabiana Henriques Machado de Melo, et al.
Theranostics|November 1, 2023
<i>In vivo</i> nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental gliomaJessica Hunger, Katharina Schregel, Berin Boztepe, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Pageof 118

Showing results (1001-1010 of 1,174) with videos related to

Sort By:
Pageof 118
Leukemia|February 24, 2021
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631Patrick A Brown, John A Kairalla, Joanne M Hilden, et al.
Blood|August 9, 2023
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group studyBrent L Wood, Meenakshi Devidas, Ryan J Summers, et al.
Blood|July 1, 2015
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232Michael J Borowitz, Brent L Wood, Meenakshi Devidas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2023
Children's Oncology Group AALL1331: Phase III Trial of Blinatumomab in Children, Adolescents, and Young Adults With Low-Risk B-Cell ALL in First RelapseLaura E Hogan, Patrick A Brown, Lingyun Ji, et al.
Pediatric Blood & Cancer|March 11, 2015
Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434Stuart S Winter, Kimberly P Dunsmore, Meenakshi Devidas, et al.
Leukemia|November 2, 2021
Outcomes in adolescent and young adult patients (16 to 30 years) compared to younger patients treated for high-risk B-lymphoblastic leukemia: report from Children's Oncology Group Study AALL0232Michael J Burke, Meenakshi Devidas, Zhiguo Chen, et al.
Nature Genetics|February 5, 2013
Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemiaJulia A Meyer, Jinhua Wang, Laura E Hogan, et al.
Neoplasia (New York, N.Y.)|July 11, 2021
miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patientsAdriana Taveira da Cruz, Aline Hunger, Fabiana Henriques Machado de Melo, et al.
Theranostics|November 1, 2023
<i>In vivo</i> nanoparticle-based T cell imaging can predict therapy response towards adoptive T cell therapy in experimental gliomaJessica Hunger, Katharina Schregel, Berin Boztepe, et al.
Haematologica|December 15, 2018
Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COGMichael J Burke, Wanda L Salzer, Meenakshi Devidas, et al.
Pageof 118